← Browse by Condition
Medical Condition

clonal cytopenia of undetermined significance

Total Trials
4
Recruiting Now
4
Trial Phases
EARLY_Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for clonal cytopenia of undetermined significance sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — clonal cytopenia of undetermined significance Clinical Trials

How many clinical trials are currently recruiting for clonal cytopenia of undetermined significance?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for clonal cytopenia of undetermined significance, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for clonal cytopenia of undetermined significance?
clonal cytopenia of undetermined significance research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a clonal cytopenia of undetermined significance clinical trial?
Eligibility criteria for clonal cytopenia of undetermined significance trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
University of Washington 1 trial
Lachelle D. Weeks, MD, PhD 1 trial
Mayo Clinic 1 trial
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT06295965
Recruiting
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Enrollment
2,000 pts
Location
United States
Sponsor
University of Washington
View Trial →
NCT06802146 EARLY_Phase 1
Recruiting
Early Intervention in High Risk CCUS
Enrollment
108 pts
Location
United States
Sponsor
Lachelle D. Weeks, MD, PhD
View Trial →
NCT03418038 Phase 2
Recruiting
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Enrollment
80 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06566742 Phase 2
Recruiting
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Enrollment
15 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

chronic myelomonocytic leukemia (2) recurrent fallopian tube carcinoma (1) recurrent ovarian carcinoma (1) recurrent primary peritoneal carcinoma (1) recurrent malignant solid neoplasm (1) clonal hematopoiesis (1) idiopathic cytopenia of undetermined significance (1) non neoplastic hematopoietic and lymphoid cell disorder (1) ovarian carcinoma (1) myeloid neoplasm post cytotoxic therapy (1) cytopenia (1) high grade b cell lymphoma with myc and bcl2 or bcl6 rearrangements (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology